Takeda gets FDA nod for Fruzaqla to treat metastatic colorectal cancer
The clearance of Fruzaqla is supported by the results from two Phase 3 trials, including the FRESCO-2 trial…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
09 Nov 23
The clearance of Fruzaqla is supported by the results from two Phase 3 trials, including the FRESCO-2 trial…
07 Nov 23
The approval was based on the IBIS-II study in which Anastrozole therapy resulted in fewer cases of breast…
03 Nov 23
The approved Type II Variation application pertains to the use of Ryeqo in women who have a history…
01 Nov 23
The FDA approval for the IL-17A inhibitor was based on the findings of a Phase 3 programme, which…
01 Nov 23
NVX-CoV2601 is an updated iteration of Novavax's initial COVID-19 vaccine NVX-CoV2373 and is tailored specifically to target the…
01 Nov 23
Stelara is an approved human interleukin-12 and interleukin-23 antagonist, which was developed by Janssen Pharmaceuticals, a subsidiary of…
31 Oct 23
The breakthrough therapy designation is intended for the treatment of patients diagnosed with previously untreated, locally advanced, or…
27 Oct 23
Omvoh is an IL-23p19 antagonist, approved to treat moderate to severely active ulcerative colitis (UC) in adults, based…
27 Oct 23
The approval is based on the positive results from the phase 3 BALATON and COMINO trials in which…
25 Oct 23
The approval was based on the data from the Phase 1, multicentre study of IDH1-mutated R/R MDS patients…